España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Pulmatrix
PULM
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$7.28
0.39
5.66%
At close: -
$6.88
-0.40
-5.49%
After Hours: 9:06 AM EDT
Get Report
Comment
Pulmatrix (PULM) Forecast
News
Earnings
Pulmatrix (PULM) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Pulmatrix (NASDAQ:PULM) Stock
Pulmatrix Stock (NASDAQ: PULM)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, November 13, 2024
Pulmatrix shares are trading higher after the...
Benzinga Newsdesk
Trading Halt: Halt status updated at 9:45:00 ...
Benzinga Newsdesk
Pulmatrix And Cullgen Announce Proposed Merge...
Benzinga Newsdesk
Trading Halt: Halted at 8:55:00 a.m. ET - Tra...
Benzinga Newsdesk
Friday, November 08, 2024
Pulmatrix Q3 EPS $(0.71) Up From $(1.03) YoY,...
Benzinga Newsdesk
Tuesday, August 13, 2024
Pulmatrix Q2 2024 Revenue $1.55M Vs $1.8M YoY...
Benzinga Newsdesk
Wednesday, May 29, 2024
Pulmatrix Enters Cross License Agreement With...
Benzinga Newsdesk
Friday, May 17, 2024
Pulmatrix Files For Mixed Shelf Of Upto $95M
Benzinga Newsdesk
Wednesday, May 15, 2024
Pulmatrix Announces Peer-Reviewed Publication...
Benzinga Newsdesk
Friday, May 10, 2024
Pulmatrix Q1 2024 EPS $0.23 Up From $(1.22) Y...
Benzinga Newsdesk
Friday, March 29, 2024
Pulmatrix Q4 EPS $(0.57) Beats $(1.04) Estima...
Benzinga Newsdesk
Wednesday, February 21, 2024
Pulmonx Sees FY24 Revenue $81M-$84M
Benzinga Newsdesk
Monday, January 08, 2024
Pulmatrix Stops PUR1900 Phase 2B Study Patien...
Benzinga Newsdesk
Thursday, November 09, 2023
Pulmatrix Q3 EPS $(1.03) Beats $(1.05) Estima...
Benzinga Newsdesk
Wednesday, October 04, 2023
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
Tuesday, September 26, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
Tuesday, September 19, 2023
Pulmatrix Announces FDA Acceptance Of IND App...
Benzinga Newsdesk
Friday, September 08, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
Wednesday, August 30, 2023
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
Tuesday, August 29, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
Wednesday, August 23, 2023
Pulmatrix Announces Publication On Physiologi...
Benzinga Newsdesk
Tuesday, August 15, 2023
HC Wainwright & Co. Reiterates Buy on Pulmatr...
Benzinga Newsdesk
Thursday, August 10, 2023
Pulmatrix Q2 EPS $(1.04) Up From $(1.36) YoY,...
Benzinga Newsdesk
Tuesday, July 11, 2023
Pulmatrix Announces Submission Of IND Application To FDA To Initiate A Phase 2 Trial Of Investigational Drug PUR3100 To Treat Acute Migraine
Happy Mohamed
Thursday, June 15, 2023
Pulmatrix Presents PUR3100 Phase 1 Data At Th...
Benzinga Newsdesk
Monday, May 15, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Pulmatr...
Benzinga Newsdesk
Friday, May 12, 2023
Pulmatrix Q1 EPS $(1.22) Up From $(1.51) YoY,...
Benzinga Newsdesk
Thursday, April 27, 2023
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
Thursday, March 30, 2023
Pulmatrix Announces Year-End And Q4 Financial 2022 Results And Provides Corporate Update; $35.6M In Cash And Cash Equivalents At The End Of 2022 Providing Cash Runway Into Q2 2024
Happy Mohamed
Monday, March 27, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
Wednesday, March 15, 2023
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
Tuesday, February 07, 2023
HC Wainwright & Co. Reiterates Buy on Pulmatr...
Benzinga Newsdesk
Monday, February 06, 2023
Pulmatrix Announces First Patient Dosed In Ph...
Benzinga Newsdesk
Monday, January 23, 2023
Pulmatrix To Present Data On PUR1800 At The A...
Benzinga Newsdesk
Wednesday, January 04, 2023
Pulmatrix Says Formulated Inhaled Migraine Candidate Safe With Fewer GI Side Effects Compared To IV
Vandana Singh
Pulmatrix Announces Top Line Results From Pha...
Benzinga Newsdesk
Thursday, November 10, 2022
Pulmatrix Q3 EPS $(1.45) Up From $(1.80) YoY,...
Benzinga Newsdesk
Monday, September 26, 2022
Pulmatrix Announces Patient Dosing Completed ...
Bill Haddad
Thursday, September 22, 2022
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
Wednesday, September 21, 2022
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights
Thursday, August 25, 2022
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
Why Splunk Is Trading Lower By Around 10%; Here Are 28 Stocks Moving Premarket
Lisa Levin
Tuesday, August 02, 2022
Pulmonx Sees FY22 Sales $55M-$60M vs $58.53M ...
Bill Haddad
Tuesday, July 12, 2022
Pulmatrix Commences Initial-Stage Acute Migraine Study
Ragothaman Srinivasan
Pulmatrix Announces First Subject Dosed In Phase 1 Study Of PUR3100 For Acute Migraine
Bill Haddad
Thursday, May 12, 2022
Pulmatrix Q1 EPS $(1.51) Up From $(1.80) YoY,...
Benzinga Newsdesk
Wednesday, March 30, 2022
HC Wainwright & Co. Maintains Buy on Pulmatri...
Benzinga Newsdesk
Tuesday, March 29, 2022
Pulmatrix FY21 EPS $(8.63) Up From $(13.43) Y...
Benzinga Newsdesk
Monday, March 21, 2022
Pulmatrix's COPD Candidate Shows Early Safety, Preliminary Pharmacokinetic Results
Vandana Singh
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
